FDA clears the first blood-based Alzheimer’s test (BIIB: NASDAQ)

Food and Drug Administration (FDA) cleared Lumipulse Gi for the United States trade as the first blood-based test that could help diagnose Alzheimer the disease.

Developed by Pennsylvania-based Fujirebio diagnosis, Lumipulse received Fda 510 ((k)) Clearance on Friday